Shandong Boan Biotechnology Co., Ltd. (06955.HK)

Shandong Boan Biotechnology Co., Ltd. is a biopharmaceutical company, which engages in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 714 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.